Role of brachytherapy in the treatment of cancers of the anal canal: Long-term follow-up and multivariate analysis of a large monocentric retrospective series by Lestrade, Laëtitia et al.
Anal canal cancers are rare, representing 
2 % of all digestive cancers and 6 % of ano-
rectal cancers, but their incidence is in-
creasing [1]. External beam radiotherapy 
(EBRT), with concomitant chemotherapy 
(CT) for advanced tumors, is the standard 
treatment for anal canal carcinoma. Ran-
domized controlled trials (RCTs) clear-
ly assessed the role of concomitant CT in 
this setting [2–4]. The optimal dose and 
schedule of EBRT is still under investiga-
tion, but the importance of delivering a 
total dose of ≥  55–59 Gy to the tumor bed 
to patients with stage II/III anal canal can-
cer is supported by retrospective studies 
showing better local control rates at these 
dose levels [5, 6]. International guidelines 
support the utility of a boost after EBRT 
± CT [7]. Brachytherapy (BRT) is con-
sidered a valuable technique for deliver-
ing the boost to T1–T2 and selected small 
T3 anal tumors responding to EBRT ± CT 
[8], but its role has not been evaluated ex-
tensively.
Indeed, the number of patients treat-
ed with BRT in the context of RCTs or in 
retrospective series is often limited; there 
are only three retrospective studies pre-
senting results of more than 200 patients 
treated with BRT, with median follow-up 
times of 36–65 months [9–11].
This study reports long-term (median 
follow-up, > 6 years) data on the efficacy 
and toxicity in a large population of pa-
tients treated with EBRT ± CT and BRT.
Patients and methods
Study population and treatment
We retrospectively reviewed the data of 
patients with histologically proven anal 
canal cancer treated with curative intent 
using EBRT ± CT and a boost delivered 
using BRT, updating the follow-up of pa-
tients who had not been seen for more 
than 12 months leading up to the date of 
this analysis. Although the EBRT ± CT 
treatment was delivered in different ra-
diotherapy departments, all the BRT pro-
cedures were performed in the same ra-
diotherapy department, ensuring the ho-
mogeneity of data with respect to BRT. 
The clinical stage of the tumors was de-
fined according to the 2002 Internation-
al Union Against Cancer Classification 
(UICC 2002) [12].
Primary endpoints were local con-
trol (LC) and acute and late toxicity rates. 
Overall (OS), cancer-specific (CSS), dis-
ease-free (DFS), colostomy-free, nod-
al relapse-free (NRFS), and metastases-
free survival (MFS) were secondary end-
points. The impact of some clinical and 
therapeutic variables on the considered 
endpoints was also evaluated and report-
ed (. Table 1).
Statistical analysis
The characteristics of the study popula-
tion and the acute and late toxicity events 
are reported by descriptive statistics. We 
considered acute toxicity as those events 
recorded up to 6 months from the end of 
treatment, while all others were consid-
ered as late toxicities.
Acute and late toxicities were retro-
spectively scored with the NCI-CTC scale 
v. 4.0 [13], while sphincter function was 
evaluated by the Womack scale [13].
LC, NRFS, and MFS times were calcu-
lated from the end of BRT until the date 
of local, nodal (inguinal and/or pelvic), 
or metastatic disease recurrence, respec-
tively (or the date of the last follow-up in 
disease-free patients). Any local, nodal, 
or systemic relapse was considered as an 
event in order to calculate the DFS rates.
OS and CSS were calculated from the 
date of the biopsy to the date of death from 
any cause or from cancer, respectively (or 
the date of the last follow-up, if alive). The 
Kaplan–Meier method was used to ana-
lyze these endpoints.
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. Table 1 summarizes the clinical and 
therapeutic features (selected from the 
available literature) studied in the uni-
variate analysis (performed by the log-
rank test). Multivariate analysis was per-
formed using the Cox regression test. A p 
value less than 0.05 was considered statis-
tically significant. Statistical analysis was 
performed using the SPSS software (SPSS 
Statistics 17.0©, 1993–2007).
Results
Patient and tumor characteristics
Between May 1992 and November 2009, 
a total of 234 patients were referred to the 
Radiation Oncology Department of the 
study center to be treated with BRT. Fif-
teen patients who received exclusive BRT 
and ten patients who were lost to follow-
up after BRT were excluded from this 
analysis; thus, the data of 209 patients are 
presented. The median follow-up for the 
whole population was 72.8 months.
. Table  2 summarizes the patient 
characteristics.
Staging procedures and 
tumor stage
All patients underwent a pretreatment 
physical examination, chest radiography, 
ultrasonography of the abdomen, routine 
laboratory tests, and tumor biopsy.
Abdominal computed tomography 
scan, magnetic resonance imaging (MRI), 
and, more recently, endorectal ultrasound 
(EUS) were also performed according to 
the treatment period (. Table 2).
We found that 85 patients (41 %) had 
a locally advanced tumor (T3–T4), while 
synchronous pelvic and/or inguinal 
lymph node metastases were observed 
in 58 patients (27 %). The total number 
of patients with T3 and T4 cancer was 80 
and 5, respectively. In particular, among 
the T4 group, three were referred to BRT 
because of a major response after the ra-
diochemotherapy (RT-CT) and two of 
them refused surgery. . Table 3 summa-
rizes the disease characteristics.
Table 1 Primary (in italics) and secondary endpoints of the study and variables considered in 
the univariate and multivariate analysis
Endpoints Variables
Local control (LC) T (1–2 vs. 3–4)
Overall survival (OS) N (0 vs. 1–3)
Cancer-specific survival (CSS) Neoadjuvant CT (yes vs. no)
Disease-free survival (PFS) Concomitant CT (yes vs. no)
Colostomy-free survival Type of concomitant CT (5-FU/CDDP vs. 5-FU/MMC vs. other)
Nodal-relapse free survival (NRFS) Dose of pelvic RT (≤ 45 Gy vs. > 45 Gy)a
Metastases-free survival (MFS) Response after RT ± CT (≤ 75 % vs. > 75 %)
Dose of BRT (< 18 Gy vs. ≥ 18 Gy)a
Total dose
LC (yes vs. no)
Inguinal RT (yes vs. no)
Pelvic volume (large vs. small)
Acute toxicity rates Smoking (yes vs. no)
Late toxicity rates Diabetes (yes vs. no)
Body mass index (BMI)
Concomitant CT (yes vs. no)
Dose of pelvic RT (≤ 45 Gy vs. > 45 Gy)a
Pelvic volume (Large vs. small)
Total dose (< 63 Gy vs. ≥ 63 Gy)a
Dose of BRT (< 18 Gy vs. ≥ 18 Gy)a
Number of implants (< 6 vs. ≥ 6)a
Length of sources (in cm) (≤ 5 vs. > 5)a
Linear activity (mCi/cm) (≤ 1.19 vs. > 1.19)a
Dose rate of BRT (Gy/h) (< 0.75 vs. ≥ 0.75)a
CT chemotherapy, RT radiotherapy, BRT brachytherapy, LC Local control, 5-FU 5-fluorouracil, CDDP cisplatin, 
MMC mitomycin C
aFor these variables, median values were chosen to identify the subgroups
Table 2 Patient characteristics
Number Percentage
Patients (n) 219 100 %
Sex
Male 36 16.44 %
Female 183 83.56 %
Age (years)
Mean 63.4
Median (range) 64 (25–88)
Performance status
0 173 79 %
1 46 21 %
Tobacco
Yes (stopped) 20 (10) 9.5 % (4.8 %)
No 185 88.5 %
Not available 4 2 %
Quantity in PA (packets/year)
Median 25
Range (1–60)
Diabetes under 
treatment
10
Type 1 8
Type 2 1
Type 2 needing 
insulin
1
Body mass index kg/m2
< 25 120
≥ 25 65
Not available 44
HIV infection 5
Symptoms
Any 7 3.4 %
Rectal bleeding 119 57.5 %
Pain 71 34.3 %
Mass/
hemorrhoids
51 24.6 %
Inguinal nodes 8 3.9 %
Rectal syndrome 27 13.0 %
Fecal transit 
problems
25 12.1 %
Other 12 5.8 %
Endorectal 
echography
136 66 %
Magnetic reso-
nance imaging
48 23.3 %
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External beam radiotherapy
All patients underwent EBRT to the anal 
canal and pelvic nodal areas. This was de-
livered with different techniques of irra-
diation according to the year of the treat-
ment and the internal protocols of the 
treating centers (. Table 4). The medi-
an dose to this volume was 45 Gy (range, 
30–56), with a median dose/fraction of 
1.8 Gy (range, 1.8–3). Only nine patients 
received hypofractionated EBRT (3 Gy/
fraction), to a median dose of 39 Gy 
(range, 36–39).
Patients presenting with a more ad-
vanced T stage (i.e., T3 and T4) received 
a median dose of BRT of 18 Gy (range, 
10–22), not statistically different from 
the rest of the patients. Regarding the 
technical aspects of the implants of pa-
tients with T4 disease, one, two, one, 
and one patients needed five, six, seven, 
or eight needles, respectively. Concern-
ing the clinical outcomes, 40 of 80 cat-
egory-T3 patients and three of five cat-
egory-T4 patients showed a response of 
greater than 75 % after the first course 
of RT-CT. Finally, 17 of 80 category-T3 
patients and one offive category-T4 pa-
tients received a colostomy for locally re-
lapsing or residual disease. Among these 
18 patients, 11 had a response of greater 
than  75 % and seven had a response of 
less than 75 %.
Median overall treatment time for 
EBRT ± CT was 36 days (range, 15–74).
Inguinal irradiation was delivered with 
a prophylactic (24 patients) or curative in-
tent (19 patients). The median dose was 
46 Gy (range, 7–60) and 45 Gy (range, 
41.4–60) in the curative and in the pro-
phylactic setting, respectively.
Brachytherapy
EBRT was always followed by a BRT boost 
using 192Ir sources, delivered with a low-
dose rate (LDR, 151 patients) or a pulse-
dose rate (PDR, 58 patients) depend-
ing on the availability of the technique 
in the department (. Table 4). BRT was 
performed following the technique de-
scribed by Papillon [9], following the sys-
tem of Paris for the dosimetry, and pre-
scribing the dose to the isodose of 85 % 
of the prescribed dos. The median dose 
Abstract · Zusammenfassung
Strahlenther Onkol 2014 ∙ 190:546–554  DOI 10.1007/s00066-014-0628-y
© Springer-Verlag Berlin Heidelberg 2014
L. Lestrade · B. De Bari · P. Pommier · X. Montbarbon · E. Lavergne · J.-M. Ardiet · C. Carrie
Role of brachytherapy in the treatment of cancers of 
the anal canal. Long-term follow-up and multivariate 
analysis of a large monocentric retrospective series
Abstract
Background and purpose. There are few 
data on long-term clinical results and tol-
erance of brachytherapy in anal canal can-
cer. We present one of the largest retrospec-
tive analyses of anal canal cancers treated 
with external beam radiotherapy with/with-
out (±) chemotherapy followed by a brachy-
therapy boost.
Materials and methods. We performed a 
retrospective analysis of clinical results in 
terms of efficacy and toxicity. The impact of 
different clinical and therapeutic variables on 
these outcomes was studied.
Results. From May 1992 to December 2009, 
209 patients received brachytherapy after ex-
ternal beam radiotherapy ± chemotherapy. 
Of these patients, 163 were stage II or stage 
IIIA (UICC 2002) and 58 were N1-3. Accord-
ing to age, ECOG performance status (PS), 
and comorbidities, patients received either 
radiotherapy alone (58/209) or radiochemo-
therapy (151/209). The median follow-up was 
72.8 months. The 5- and 10-year local con-
trol rates were 78.6 and 73.9 %, respective-
ly. Globally, severe acute and late G3–4 reac-
tions (NCI-CTC scale v. 4.0) occurred in 11.2 
and 6.3 % of patients, respectively. Univariate 
analysis showed the statistical impact of the 
pelvic treatment volume (p = 0.046) and of 
the total dose (p = 0.02) on the risk of severe 
acute and late toxicities, respectively. Only six 
patients required permanent colostomy be-
cause of severe late anorectal toxicities.
Conclusion. After a long follow-up time, 
brachytherapy showed an acceptable toxicity 
profile and high local control rates in patients 
with anal canal cancer.
Keywords
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Brachytherapy · Toxicity · Local control
Stellenwert der Brachytherapie bei der Behandlung von 
Tumoren des Analkanals. Langzeit-Follow-up und multivariate 
Analyse einer großen monozentrischen, retrospektiven Studie
Zusammenfassung
Hintergrund und Ziel. Es gibt gegenwärtig 
nur wenige klinische Daten zu den Ergebnis-
sen und Nebenwirkungen von Brachythera-
pie bei Analkanaltumoren. Wir präsentieren 
die Daten einer der größten retrospektiven 
Auswertungen für die Behandlung von Anal-
kanaltumoren mit perkutaner Radiothera-
pie ± simultaner Chemotherapie, gefolgt von 
einem Brachytherapie-Boost.
Material und Methoden. Wir analysier-
ten retrospektiv die Patientendaten hinsicht-
lich Toxizität und Tumorkontrolle. Der Ein-
fluss verschiedener klinischer und therapeu-
tischer Variablen auf das Outcome der Patien-
ten wurde untersucht.
Ergebnisse. Zwischen Mai 1992 und Dezem-
ber 2009 erhielten 209 Patienten eine Brachy-
therapie nach perkutaner Strahlentherapie 
± simultaner Chemotherapie. Hiervon waren 
163 Patienten Stadium II oder IIIA (UICC 2002) 
und 58 N1-3. Entsprechend ihres Alters, 
ECOG-Status und Komorbiditäten erhielten 
die Patienten entweder eine alleinige Strah-
lentherapie (58/209) oder eine kombinierte 
Radiochemotherapie (151/209). Die mediane 
Nachbeobachtungszeit lag bei 72,8 Monaten. 
Die lokale Kontrolle nach 5 bzw. 10 Jahren lag 
bei 78,6 % bzw. 73,9 %. Schwere akute bzw. 
chronische Therapienebenwirkungen (G3-G4 
nach NCI-CTC-Scale v. 4.0) traten in 11,2 % 
bzw. 6,3 % der Fälle auf. Univariate Analysen 
zeigten einen Einfluss des pelvinen Bestrah-
lungsvolumens (p = 0,046) und der Gesamt-
dosis(p = 0,02) für das Risiko, schwerwiegen-
de akute oder chronische Nebenwirkungen 
zu entwickeln. Lediglich 6/209 Patienten be-
nötigten die Anlage eines dauerhaften Kolos-
tomas aufgrund schwerwiegender anorekta-
ler Toxizitäten.
Schlussfolgerung. Nach langer Nachsorge-
zeit zeigte die Brachytherapie bei Analkanal-
tumoren ein akzeptables Nebenwirkungspro-
fil bei hoher lokaler Kontrolle.
Schlüsselwörter
Analkanaltumor · Radiotherapie · 
Brachytherapie · Toxizität · Lokale Kontrolle
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was 18 Gy (range, 10–31.7). The median 
time of application was 22 h (range, 11–
77), and the median interval between the 
end of EBRT ± CT and BRT was 32 days 
(range, 12–151).
Chemotherapy
Eighteen patients received neoadjuvant 
CT, and CDDP + 5-FU was given to 17 of 
18 patients. Because of renal toxicity after 
the first cycle of CT, one patient received 
carboplatin AUC5 instead of CDDP dur-
ing the last cycle.
Concomitant CT was delivered to 151 
patients, most of whom (89 %) received 
CDDP + 5-FU (69 %) or 5-FU + MMC 
(20 %). . Table 4 summarizes the data 
for concomitant CT.
Clinical results: primary endpoints
Local control
Clinical response after the EBRT was eval-
uated by digital rectal examination (DRE) 
with the patient under general anesthesia 
just before the BRT procedure; this infor-
mation was available for 198 of 209 pa-
tients. Response was rated as less than 
Table 3 Disease characteristics
Patients 
(n)
%
Location
Anal canal 106 50.7
Anal canal reaching anal 
margin
41 19.6
Rectoanal area 55 26.3
Anal margin 2 1.0
Anal canal, anal margin, 
and rectum
2 1.0
Not available 3 1.4
Tumor
T1 26 12.4
T2 98 46.9
T3 80 38.3
T4 5 2.4
Not available
Histologic grade distribution
Carcinoma in situ 4 1.9
Large-cell keratinizing 
squamous cell carcinoma
56 26.8 %
Non-keratinizing squa-
mous cell carcinoma
120 57.4 %
Basaloid squamous cell 
carcinoma
17 8.1
Adenocarcinoma of 
rectal—anal glands type
5 2.4
Carcinoma with small cells 1 0.5
Undifferentiated carci-
noma
1 0.5
Other tumors (sarco-
mas—lymphomas—
melanomas)
1 0.5
Cloacogenic 3 1.4
Not available 1 0.5
HPV 11 5.2
Nodal status
N0 151 72.3
N1 36 17.2
N2 15 7.2
N3 7 3.3
Staging TNM
I 22 10.5
II 125 59.8
IIIA 38 18.2
IIIB 24 11.5
Histological procedures
Biopsy only 194 92.8
Surgical margin R0 4 1.9
Surgical margin R1 6 2.9
Surgical margin R2 5 2.4
Squamous cell carcinoma 
antigen (median value 
and range)a
1.95 ng/ml 
(0–11.7)
aAvailable for only 17 patients
External beam radiation therapy (EBRT)
Treating center (patients)
Current study center 78 37.3 %
Others 131 62.7 %
Decubitus (patients)
Ventral 9 4.3 %
Dorsal 200 95.7 %
Total dose (Gy)
Median (range) 45 (36–56)
Median dose/fraction 
(range)
1.8 (1.8–3)
Pelvic volume (patients)
“Small pelvis” (upper 
border up to S3)
165 79.0 %
“Large pelvis” (upper 
border up to L5)
41 19.6 %
Not available 3 1.4 %
Inguinal irradiation (patients)
No 161 77.0 %
Unilateral 6 2.9 %
Bilateral 42 20.1 %
Type of beams (patients)
Photons 201 96.2 %
Photons + perineal 
field (electrons)
4 1.9 %
60Cobalt 4 1.9 %
Field arrangement (patients)
Orthogonal fields 
(2–4 fields)
159 76 %
Direct perineal fields 
+ orthogonal fields 
(2–4 fields)
38 18.3 %
Intensity modulated 
radiation therapy
4 1.9 %
Not available 8 3.8 %
Median number of 
fractions (range)
25 (12–28)
RT duration in days 
(range)
36 (15–74)
Brachytherapy (BRT)
Median interval be-
tween EBRT and BRT 
in days (range)
32 (12–151)
BRT technique (patients)
Low-dose rate 151 72.2 %
Pulsed-dose rate 58 27.8 %
Median dose (range) 18 (10–31.7)
Median duration of 
BRT in hours (range)
22 (11–77)
Linear activity (mCi/
cm, range)
1.19 
(0.71–1.68)
Dose rate (Gy/h, 
range)
0.75 
(0.23–1.25)
Number of sources 
(range)
6 (4–12)
Table 4 Radiotherapy and chemotherapy
External beam radiation therapy (EBRT)
Median length of 
sources (cm, range)
5 (4–9)
Median total 
dose EBRT + BRT 
(Gy, range)
63 (51–76.7)
Concomitant chemotherapy
Schedule (patients)
During the 1st week 
of EBRT
18 11.9 %
During the 1st and 5th 
week of EBRT
123 81.5 %
Weekly 10 6.6 %
Chemotherapy protocol
5FU-CDDP 104 68.9 %
5FU-MMC 31 20.5 %
Weekly CDDP 40 mg 6 4 %
Weekly carboplatin 3 1.9 %
5FU-carboplatin 3 1.9 %
Weekly CDDP 30 mg 1 0.7 %
5FU-leucovorin 1 0.7 %
Xeloda–MMC 1 0.7 %
Weekly MMC 1 0.7 %
5-FU 5-fluorouracil, CDDP cisplatin, MMC mito-
mycin C
Table 4 continued
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25 % in two patients, between 25 and 50 % 
in 16 patients, between 50 and 75 % in 78 
patients, and 75 % or greater in 102 pa-
tients.
Median LC time was not reached, with 
5- and 10-year LC rates of 78.6 and 73.9 %, 
respectively (. Fig. 1). . Figure 1 shows 
the impact of LC on the considered sec-
ondary endpoints.
Toxicity
Data on toxicity were available for 205 of 
209 patients. The global rates of G3–G4 
acute and late toxicity were 11.2 % and 
6.3 %, respectively (. Table 5).
Of the 209 patients, 44 (21 %) under-
went colostomy, 38 because of a local re-
lapse and six to treat a G4 anorectal toxic-
ity. Five- and 10-year CFS rates were 79.4 
and 75.5 %, respectively.
Two of the nine patients treated with 
the hypofractionated schedule present-
ed with a G3 acute toxicity (one with anal 
toxicity and the other with cutaneous tox-
icity) and none of them presented with 
G3–G4 late toxicity.
Sphincter function was evaluated in 
the remaining 165 patients and classified 
with the Womack scale [14] as score A 
(total continence) in 135 patients (82 %), 
score B (incontinence to gas) in 25 pa-
tients (15 %), and score C (incontinence 
to liquid stools) in five patients (3 %).
Grade 3 chemotherapy-related acute 
toxicities were recorded in seven of 151 
patients (4.6 %), with four patients pre-
senting with CDDP-related renal tox-
icity, and three patients presenting with 
neutropenia, 5-FU-related cardiac tox-
icity, or gastrointestinal toxicity, respec-
tively. No G4 acute toxicity was record-
ed. Treatment was interrupted (> 7 days) 
in only two patients and no patient failed 
to complete EBRT ± CT.
Clinical results: secondary 
endpoints
Survival rates
. Table  6 shows the 5-year OS, CSS, 
DFS, NRFS, and MFS rates (median, not 
reached).
The 10-year OS, CSS, DFS, NRFS, and 
MFS rates were 65.7, 81, 49.4, 78.5, and 
88.8 %, respectively.
Clinical results: univariate 
and multivariate analysis
Regarding the impact of the variables 
on the primary endpoints (. Table 6), 
BRT dose influenced LC, with lower dos-
es showing better outcomes (p = 0.003). 
It should be noted that there was a sta-
tistical relationship between the total 
BRT dose (< 18 Gy vs. > 18 Gy) and ob-
jective response at clinical evaluation by 
DRE before BRT, with higher doses deliv-
ered to patients showing worse response 
(p = 0.001). LC statistically influenced 
all the considered endpoints (p < 0.001). 
. Figure 2 shows the impact of the BRT 
dose onthe secondary endpoints consid-
ered.
Multivariate analysis confirmed the 
statistical impact of concomitant CT on 
OS (HR: 0.55, 95% CI 0.3–0.99, p = 0.008) 
and of LC on OS (HR: 0.25, 95% CI 0.14–
0.45, p < 0.001) and on CSS (HR: 0.09, 
95% CI 0.04–0.21, p < 0.001).
A total dose higher than the medi-
an total dose was the only variable that 
significantly influenced the risk of de-
veloping severe late toxicity, with rates 
of 2.7 and 10 % for doses of ≤ 63 Gy or 
> 63 Gy (p = 0.02), respectively. The glob-
al incidence of G1–G4 severe toxicity was 
Table 5 Acute and late toxicity
Acute toxicity Late toxicity
Grade 1–2 Grade 3 Grade 1–2 Grade 3–4
Skin 102 12 6 0
Diarrhea 138 3 19 0
Anal 132 8 64 10
Rectal 39 1 78 4
Vulvar 15 2 0 0
Vaginal 12 1 8 0
Urinary 18 1 5 0
Table 6 Clinical outcomes with results of univariate and multivariate analysis
5-year 
LC
5-year 
OS
5-year 
CSS
5-year 
DFS
5-year 
CFS
5-years 
NRFS
5-years 
MFS
Overall population (%) 78.6 80.9 85.7 69.4 79.4 82.1 90.5
T
T1–T2 (%) 79.6 84.9 88.6 70.1 80.5 87.4 94.8
T3–T4 77.3 75.9 82.0 68.4 77.7 74.6 84.7
p 0.5 0.13 0.14 0.94 0.50 0.006 0.08
Neoadjuvant CT
Yes(%) 81.6 74.9 79.3 69.0 82.4 88.5 76.7
No (%) 78.9 82.0 86.2 72.2 79.6 81.5 91.8
p 0.85 0.91 0.69 0.71 0.79 0.46 0.047
Concomitant CT
Yes (%) 80.3 84.7 88.8 76.7 80.6 81.5 91.4
No (%) 74.0 70.6 77.2 67.1 75.6 84.1 87.6
p 0.16 0.026 0.011 0.54 0.22 0.72 0.15
LC – –
Yes (%) 89.5 94.7 96.1 90.9 96.1
No (%) 51.8 55.4 19.8 51.3 70.6
p < 0.0001 < 0.0001 < 0.001 < 0.0001 < 0.0001
BRT dose
< 18 Gy (%) 88.8 91.4 92.5 68.2 88.5 88.0 94.9
≥ 18 Gy (%) 72.2 74.7 81.5 69.7 73.6 78.4 87.8
p 0.003 0.045 0.047 0.37 0.002 0.09 0.08
LC local control, OS overall survival, CSS cancer-specific survival, DFS disease-free survival, CFS colostomy-free 
survival, NRFS nodal relapse-free survival, MFS metastases-free survival, CT chemotherapy, BRT brachytherapy
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influenced by the number of sources used 
(≥ 6 vs. < 6, 71.5 vs. 56.2 %, p = 0.014). Fi-
nally, a strong relationship was seen be-
tween pelvic volume and pelvic dose lev-
els and the risk of late severe toxicity, but 
it was not significant (p = 0.05).
None of the other variables influenced 
the primary and secondary endpoints 
considered in this study and are therefore 
not reported in . Table 6.
Discussion
BRT is an important therapeutic option 
in the treatment of anal canal cancers, 
but its role has not been evaluated exten-
sively [8]. We report the long-term effica-
cy and safety data in a large population of 
more than 200 patients treated with EBRT 
± CT and BRT, with the longest median 
follow-up of 72.8 months. To date, only 
three retrospective studies enrolled more 
than 200 patients treated with BRT: Pa-
pillon et al. (221 patients and > 36 months 
of follow-up), Chapet et al. (218 patients, 
58 months of follow-up), and Tournier-
Rangeard et al. (233 patients, 65 months 
of median follow-up) [9–11]. Only a few 
patients enrolled in RCTs on anal canal 
cancer were treated with BRT [2–4].
Despite its retrospective nature and 
some biases inherent to the data collec-
tion on the EBRT ± CT course (especially 
for the toxicity reporting), this study is of 
interest for several reasons.
Firstly, in the last two decades, ther-
apeutic innovations introduced into the 
daily clinical practice of radiation on-
cologists (such as neoadjuvant/concom-
itant/adjuvant CT schedules, the rap-
id evolution of EBRT from 2D-EBRT to 
3D-EBRT and, more recently, to differ-
ent promising IMRT techniques) radi-
cally changed the approach to managing 
anorectal cancer patients [7, 15, 16]. Al-
though there is good evidence on the effi-
cacy of concomitant CT in the treatment 
of locally advanced anal canal cancers [7, 
17] and in recent retrospective reports on 
the treatment of localized tumors [18] and 
in particular populations of patients, such 
as elderly or HIV-positive patients [19, 20, 
21], the clinical meaning of the dosimetric 
advantages of these technical innovations 
must still be prospectively evaluated in 
terms of efficacy and toxicity, in the con-
text of a Health Technology Assessment 
[22], as was recently stated by the Euro-
pean Society of Radiotherapy and Oncol-
ogy [23]. Considering the difficulties in 
obtaining the same high-level evidence 
by RCTs and the potential selection bi-
as, these trials do not represent “real-life” 
conditions. For these reasons, benchmark 
data are strongly needed when adopting 
other types of perspective evaluation of 
different treatment techniques and mo-
dalities, particularly for rare cancers like 
anal canal cancer.
Moreover, it is difficult to obtain his-
torical data for BRT in anal canal cancer, 
as it is not widely performed. Last but not 
least, considering the potential impact of 
the experience on the efficacy and safety of 
BRT procedure, it is important to accumu-
late evidence in high-volume radiothera-
py centers, assessing and confirming clin-
ical results over a long period of follow-up.
In this context, our 5-year LC rate 
of 78.6 % is comparable to the results of 
the three RCTs (ranging between 68 and 
87 %) and to those of Tournier-Rangeard 
et al. (80.8 %) and of Papillon et al. (80 %, 
published in 1989) [9, 11]. Chapet et al. 
did not give 5-year LC rates, as they only 
reported data for 5-year CFS (61.5 %) and 
DFS (60 %) rates [10]. Our results confirm 
the efficacy and the safety of BRT. The 
large number of patients and the long fol-
low-up make our series one of the most 
important benchmark datasets in this 
clinical and therapeutic setting.
Univariate analysis indirectly supports 
the prognostic role of the clinical response 
after EBRT ± CT reported by Wagner et 
al. and Peiffert et al., who suggested that 
lower doses of BRT could be delivered if 
there is complete response after EBRT ± 
CT [24, 25]. In our analysis, there was a 
statistical relationship between the to-
tal BRT dose (< 18 Gy vs. > 18 Gy) and 
clinical response at clinical evaluation by 
DRE before BRT, with higher doses deliv-
ered to patients showing worse response 
(p = 0.001), but also with lower dos-
es showing better outcomes (p = 0.003). 
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ered (all p < 0.001)
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Moreover, it should be noted that the risk 
of late toxicity was influenced by the to-
tal dose of EBRT and the number of im-
plants, typically both larger in poorly re-
sponding patients.
These results could be interpreted as a 
potential limit of BRT, i.e., that BRT can-
not compensate for a poor response to 
EBRT ± CT, even using higher doses, and 
moreover could be more toxic in poorly 
responding patients.
In contrast to the published literature 
reporting the impact of T and N stage [4] 
and/or time between the end of EBRT ± 
CT and boost [26] and/or tumor response 
before BRT [10] and/or total dose of 
EBRT [27, 28], none of the other studied 
clinical and therapeutic variables statisti-
cally influenced LC on multivariate anal-
ysis. The decision to use the median val-
ues (when indicated) as cut-offs in analyz-
ing some of these variables (. Table 1) in 
order to have equally represented popula-
tions could explain these differences with 
the literature. We cannot exclude that dif-
ferent cut-offs would yield different statis-
tical results, but we considered the choice 
of the median values a more “objective” 
way to distribute our population.
This study is also an important bench-
mark showing the safety of BRT with 
rates of 11.2 and 6.2 % of acute and late 
severe toxicity, respectively. Published 
RCTs showed 54–74 % of G3–G4 nonhe-
matologic acute toxicity and 11–36 % of 
G3–G4 nonhematologic late toxicity [2–
4]. It should be noted that late complica-
tions of radiotherapy are poorly record-
ed in these phase III trials, as more uni-
form scores specifically addressed to radi-
ation therapy toxicity were not available at 
the time of these trials, and also because 
acute toxicity could not be directly com-
pared as different scoring systems were 
used. Looking at larger BRT studies, Cha-
pet et al. [10] reported 60 % of radiation-
induced acute toxicity, mainly G2 painful 
perineal skin, while the other two studies 
did not give data on acute toxicity [9, 11]. 
Concerning late toxicity, and particularly 
anorectal toxicity, 13 of 286 patients un-
derwent colostomy for G4 toxicity in the 
study of Tournier-Rangeard et al., but they 
did not report the rate of colostomy in the 
two groups of boost technique delivery 
(EBRT, 24 patients vs. BRT, 233 patients) 
[11]. Chapet et al. reported a global rate of 
late G3–G4 toxicity of 23.4 %, with 13 of 
221 patients (5.8 %) undergoing colosto-
my because of treatment-related toxicity 
[10]. In the study of Papillon et al. [9], G3–
G4 late complications were uncommon, 
with seven of 221 cases (3.1 %) of colosto-
my. These authors underlined the impor-
tance of strictly following the BRT proce-
dure and, in particular, the importance of 
maintaining an intersource spacing great-
er than 1.5 cm. These results are similar 
to our rates of G3–G4 late toxicity (6.2 %) 
and toxicity-related colostomy (6/219 pa-
tients, 2.8 %). The results of the particu-
lar subgroup of T3–T4 patients should 
also be discussed: Generally, T4 anal ca-
nal tumors are not considered good can-
didates for BRT, because of the high risk 
of toxicity, as they usually require many 
more needles. In our experience, we treat-
ed five patients with T4 disease, three af-
ter a major response to RT-CT and two 
young patients (52 and 57 years old) re-
fusing surgery. Four of these five patients 
are disease-free after at least 36 months 
post-BRT. This population is obviously 
too small to draw any conclusion about 
the potential value of BRT in this clinical 
setting, but it could be interesting to eval-
uate it, in particular for patients presenting 
with a major response after RT-CT.
Univariate analysis did not show tech-
nical BRT-related variables statistically 
influencing the risk of late G3–G4 toxici-
ty. In the only study specifically addressed 
to BRT toxicity, the total dose of BRT and 
the total delivered dose (EBRT ± CT and 
BRT) statistically increased the rate of 
toxicity [25]. Our study confirms the sig-
nificant impact of total dose on the risk of 
late severe toxicities. By contrast, Touboul 
et al. did not did not confirm this associ-
ation [29].
The problem about the optimal tech-
nique for delivering boost (EBRT vs. 
BRT) is not solved, as a direct relation-
ship between BRT and anorectal severe 
late toxicity has never been clearly proven.
It should benoted that patients in all 
the larger studies, except for some patients 
in the study of Tournier-Rangeard et al., 
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were treated with 2D-EBRT. The promis-
ing impact of the routine use of 3D- with 
IMRT techniques and, more recently, of 
volumetric arc and helical EBRT as well 
as image-guided EBRT has not been ex-
tensively explored. The potential clinical 
benefits of the dosimetric advantages of 
these techniques in the treatment of anal 
canal cancer patients should be prospec-
tively evaluated [30, 31].
Moreover, the introduction of new 
BRT techniques, such as high-dose rate 
BRT (HDR-BRT), with or without mod-
ern EBRT ± CT, raises other clinical and 
technical issues that need to be prospec-
tively analyzed: An interesting study by 
Saarilahti et al., combining IMRT and 
HDR-BRT for the treatment of anal ca-
nal cancer patients, showed that “…IMRT 
significantly reduces acute radiotherapy-
associated adverse events in patients treat-
ed by chemoradiotherapy for anal cancer. 
A combination of external radiotherapy 
and HDR brachytherapy may reduce the 
risk of late radiation proctitis…” [32].
In the era of tailored oncologic treat-
ments, reflection is needed to assess the 
optimal treatment approach. As already 
suggested by Chapet et al. and by Tourni-
er-Rangeard et al., EBRT ± CT and BRT 
should probably be preferred in the treat-
ment of localized tumors, while a more ag-
gressive approach, which could also inte-
grate surgery for poorly responding pa-
tients, should be considered for locally ad-
vanced cancers. Knowledge of the risks of 
toxicity and disease relapse would help cli-
nicians in their decision-making process.
Conclusion
This long-term analysis of a large popu-
lation of patients with anal canal cancer 
confirms that BRT is safe and effective in 
the treatment of these patients. Our da-
ta indicate that a dose greater than 63 Gy 
does not improve the clinical outcomes 
of the patients, but it seems to be statis-
tically more toxic. The role of BRT in the 
treatment of more advanced but well-re-
sponding tumors should be further in-
vestigated. Prospective studies are need-
ed to assess better its role in the multi-
disciplinary and tailored approach to this 
disease.
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